Pay in 4 interest-free payments of $5.86 Learn more
Ships within 48 hours · Estimated delivery Nov 1 - Nov 6
Scientific Background on BPC-157 (Body Protection Compound-157) BPC-157 is a stable synthetic pentadecapeptide derived from a protective protein in human gastric juice
Diabetes 5 , 207215 (2013)
The first phase 3 retatrutide trial, TRIUMPH-4, top-line data announced today Retatrutide, a triple GLP-1,GIP, glucagon agonist studied in patients with obesity and osteoarthritis 28.7% weight loss at 68 weeks Reduced key cardiometabolic risk markers non-HDL cholesterol, triglycerides, and hsCRP Highest dose lowered systolic BP by 14 mmHg Reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function GI side effects most common adverse event We now await 7 additional phase 3 trials in other obesity related comorbidities Retatrutide May Redefine Multi-Receptor Therapeutics Triple agonism (GLP-1 + GIP + glucagon) isnt just about adding more receptors this distinct mechanism can boost energy expenditure, not just suppress appetite
Note the injection site in a log or on your body map so you remember to rotate to a different spot next time
SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging
US$ 21.35
US$ 25.40
US$ 24.97
US$ 21.68
US$ 25.74
US$ 25.76
US$ 26.40
